Form 8-K - Current report:
SEC Accession No. 0001193125-22-032683
Filing Date
2022-02-09
Accepted
2022-02-09 16:10:55
Documents
12
Period of Report
2022-02-09
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K d267319d8k.htm   iXBRL 8-K 24331
  Complete submission text file 0001193125-22-032683.txt   148563

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA agle-20220209.xsd EX-101.SCH 2851
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20220209_lab.xml EX-101.LAB 18758
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20220209_pre.xml EX-101.PRE 11707
6 EXTRACTED XBRL INSTANCE DOCUMENT d267319d8k_htm.xml XML 3472
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 22607321
SIC: 2834 Pharmaceutical Preparations